Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bonus Therapeutics Ltd. operates within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This matter is assigned to 1 distinct examiner and is located in 1 distinct art unit, showing a singular focus for current prosecution. This concentration means that the company's immediate patent strategy is centralized under a specific individual and department.
Lindsay Michelle Dunn is the busiest examiner for this portfolio, with 1 pending office action. Since there is only 1 active action, the company's immediate success in the patent office is tied to the review process of this specific examiner and the standards of their art unit. This limited volume suggests a targeted approach to its current patent filings. The reliance on 1 distinct examiner and 1 distinct art unit requires a strategy tailored to the specific standards of the Biotechnology & Pharmaceuticals examination division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563558 | COMPOSITIONS OF CELLS WITH AN ENHANCED THERAPEUTIC CAPACITY | DUNN, LINDSAY MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563558 | COMPOSITIONS OF CELLS WITH AN ENHANCED THERAPEUTIC CAPACITY | DUNN, LINDSAY MICHELLE | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBonus Therapeutics Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lindsay Michelle Dunn has the most, with 1 of Bonus Therapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
